- Home
- RSVR vs VNDA Comparison
RSVR vs VNDA Comparison
Compare RSVR & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RSVR | VNDA |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.9M | 474.0M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | RSVR | VNDA |
|---|---|---|
| Price | $9.82 | $9.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $11.50 | ★ $14.90 |
| AVG Volume (30 Days) | 123.0K | ★ 3.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $10.95 | $21.50 |
| Revenue Next Year | $4.13 | $38.67 |
| P/E Ratio | $77.14 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $6.56 | $3.81 |
| 52 Week High | $10.32 | $9.91 |
Technical Indicators
Market Signals| Indicator | RSVR | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 78.74 | 63.29 |
| Support Level | $7.31 | $7.39 |
| Resistance Level | $10.32 | $9.60 |
| Average True Range (ATR) | 0.30 | 0.61 |
| MACD | 0.12 | 0.19 |
| Stochastic Oscillator | 82.29 | 75.38 |
Price Performance
Historical ComparisonAbout RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.